PubMed RSS Feed - -Oral Sarecycline for Treatment of Papulopustular Rosacea: Results of a Pilot Study of Effectiveness and Safety

[rss]

J Drugs Dermatol. 2021 Apr 1;20(4):426-431. doi: 10.36849/JDD.2021.5923.

ABSTRACT

BACKGROUND: Cutaneous rosacea is a common inflammatory skin disorder that often presents with facial papulopustular lesions that are frequently bothersome to patients. Broad-spectrum oral tetracyclines, such as doxycycline and minocycline, have been well established over several years of real-world use as effective agents for papulopustular rosacea. Sarecycline is a third-generation narrow-spectrum oral tetracycline that was approved for the treatment of acne in the United States in 2018.

OBJECTIVE: Studies have shown sarecycline to be effective and safe for acne, with low risk of side effects that are historically associated with oral tetracyclines, in addition to offering a reduced risk of emergence of resistant bacteria due to a narrower spectrum of antibiotic activity.

METHODS: A 12-week, investigator-blinded, controlled pilot study was completed evaluating once daily sarecycline, using weight-based oral dosing as recommended for acne, for the treatment of papulopustular rosacea in adult subjects.

RESULTS: Sarecycline was shown to be effective and safe for the treatment of papulopustular rosacea in adults with marked superiority in efficacy as compared to subjects in the control group. This article reviews the results of this pivotal study.

PMID:33852248 | DOI:10.36849/JDD.2021.5923

{url} = URL to article